Compare Barclays PLC (BCS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Barclays PLC vs State Street SPDR S&P Biotech ETF — how do they compare? Barclays PLC trades at $28 (market cap $93.87B), while State Street SPDR S&P Biotech ETF trades at $158.26. The key difference: Barclays PLC pays a 2.19% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| BCS | XBI | |
|---|---|---|
Market Cap | $93.87B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $28.56 | $164.28 |
52-Week Low | $19.36 | $86.92 |
Dividend Yield | 2.19% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Barclays PLC
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
